| [1] |
Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?[J]. Ann Surg, 2008, 247(3):456-462.
|
| [2] |
Okusaka T, Nakamura M, Yoshida M, et al. Clinical practice guidelines for pancreatic cancer 2019 from the Japan pancreas society: a synopsis[J]. Pancreas, 2020, 49(3):326-335.
|
| [3] |
Marmor S, Burke EE, Portschy PR, et al. Lymph node evaluation for treatment of adenocarcinoma of the pancreas[J]. Surg Oncol, 2015, 24(3):284-291.
|
| [4] |
Burke EE, Marmor S, Virnig BA, et al. Lymph node evaluation for pancreatic adenocarcinoma and its value as a quality metric[J]. J Gastrointest Surg, 2015, 19(12):2162-2170.
|
| [5] |
Tol JAMG, Gouma DJ, Bassi C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS)[J]. Surgery, 2014, 156(3):591-600.
|
| [6] |
Benassai G, Mastrorilli M, Mosella F, et al. Significance of lymph node metastases in the surgical management of pancreatic head carcinoma[J]. J Exp Clin Cancer Res, 1999, 18(1):23-28.
|
| [7] |
Gockel I, Domeyer M, Wolloscheck T, et al. Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space[J]. World J Surg Oncol, 2007, 5:44.
|
| [8] |
Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phaseⅡ trial of the AIO pancreatic cancer group[J]. Ann Oncol, 2023, 34(1):91-100.
|
| [9] |
Wu W, Wang XA, Wu X, et al. Total mesopancreas excision for pancreatic head cancer: analysis of 120 cases[J]. Chin J Cancer Res, 2016, 28(4):423-428.
|
| [10] |
Safi SA, Haeberle L, Fluegen G, et al. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival[J]. Pancreatology, 2021, 21(4):787-795.
|
| [11] |
Ramia JM, De-la-Plaza R, Manuel-Vazquez A, et al. Systematic review of the mesopancreas: concept and clinical implications[J]. Clin Transl Oncol, 2018, 20(11):1385-1391.
|
| [12] |
Wang Z, Ke N, Wang X, et al. Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study[J]. Medicine, 2021, 100(35):e26918.
|
| [13] |
杨尹默. 胰十二指肠切除术中淋巴结清扫范围争议与共识[J].中国实用外科杂志, 2016, 36(8):843-846.
|
| [14] |
Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy[J]. Surgery, 2003, 133(5):521-527.
|
| [15] |
Doi R, Kami K, Ito D, et al. Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer[J]. World J Surg, 2007, 31(1):147-154.
|
| [16] |
Sakai M, Nakao A, Kaneko T, et al. Para-aortic lymph node metastasis in carcinoma of the head of the pancreas[J]. Surgery, 2005, 137(6):606-611.
|
| [17] |
Safi SA, Rehders A, Haeberle L, et al. Para-aortic lymph nodes and ductal adenocarcinoma of the pancreas: distant neighbors?[J]. Surgery, 2021, 170(6):1807-1814.
|
| [18] |
Sperti C, Gruppo M, Blandamura S, et al. Para-aortic node involvement is not an independent predictor of survival after resection for pancreatic cancer[J]. World J Gastroenterol, 2017, 23(24):4399-4406.
|
| [19] |
Hempel S, Plodeck V, Mierke F, et al. Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection[J]. Sci Rep, 2017, 7(1):7688.
|
| [20] |
Birrer DL, Golcher H, Casadei R, et al. Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care. pooled data from 3 randomized controlled trials[J]. Ann Surg, 2021, 274(5):713-720.
|
| [21] |
Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase Ⅲ PREOPANC trial[J]. J Clin Oncol, 2020, 38(16):1763-1773.
|
| [22] |
Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(7):963-969.
|
| [23] |
Macedo FI, Picado O, Hosein PJ, et al. Does neoadjuvant chemotherapy change the role of regional lymphadenectomy in pancreatic cancer survival?[J]. Pancreas, 2019, 48(6):823-831.
|
| [24] |
Barrak D, Villano AM, Moslim MA, et al. Total neoadjuvant treatment for pancreatic ductal adenocarcinoma is associated with limited lymph node yield but improved ratio[J]. J Surg Res, 2022, 280:543-550.
|
| [25] |
Rahim MK, Okholm TLH, Jones KB, et al. Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes[J]. Cell, 2023, 186(6):1127-1143, e18.
|